quinazolines has been researched along with Diabetes Mellitus, Adult-Onset in 150 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.33) | 18.2507 |
| 2000's | 11 (7.33) | 29.6817 |
| 2010's | 132 (88.00) | 24.3611 |
| 2020's | 5 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Liao, J; Lu, Q; Niu, C; Wang, H; Wang, S; Yu, Y | 1 |
| Bayati, B; Emamgholipour, Z; Faramarzi, MA; Firoozpour, L; Foroumadi, A; Hekmati, M; Hosseini, FS; Moghadam, MS; Mojtabavi, S; Peytam, F; Sadat-Ebrahimi, SE; Tehrani, MB | 1 |
| Chiba, K; Kato, Y; Sarashina, A; Tatami, S | 1 |
| Devi, RV; Singh, CB; Singh, OJ; Surbala, L | 1 |
| Hashiguchi, Y; Hosoyamada, K; Imamura, N; Kajiya, S; Kamada, T; Komorizono, Y; Koriyama, N; Shinmaki, H; Tsukasa, M; Ueyama, N | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Klupczynska, A; Kokot, ZJ; Moch, M; Plewa, S; Sobańska, K; Szałek, E; Wolc, A | 1 |
| Badal, D; Bhadada, SK; Bhansali, A; Bhansali, S; Dutta, P; Mukherjee, S; Sachdeva, N | 1 |
| Scheen, AJ | 5 |
| Emser, A; Gallwitz, B; Rosenstock, J; von Eynatten, M; Woerle, HJ | 1 |
| Gong, Y; Inagaki, N; Kagimura, T; Murai, M; Patel, S; Watada, H; Woerle, HJ | 1 |
| Emser, A; Gong, Y; von Eynatten, M; Woerle, HJ | 1 |
| Duh, D; Tanret, I | 1 |
| Gong, Y; Tong, N; Woerle, HJ; Yan, S; Yang, JK; Zeng, Z; Zhang, X | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Grunberger, G | 1 |
| Barnett, AH; Huisman, H; Jones, R; Patel, S; von Eynatten, M; Woerle, HJ | 1 |
| Morley, J; Sinclair, A | 1 |
| Cooper, ME; Emser, A; Groop, PH; Perkovic, V; von Eynatten, M; Woerle, HJ | 1 |
| Bhattacharya, S; Durán-Garcia, S; Patel, S; Pinnetti, S; Rosenstock, J; Thiemann, S; Woerle, HJ; Yki-Järvinen, H | 1 |
| Haak, T; Jones, R; Meinicke, T; von Eynatten, M; Weber, S; Woerle, HJ | 2 |
| Barnett, AH; Lewin, AJ; McGill, JB; Neubacher, D; Patel, S; von Eynatten, M; Woerle, HJ | 1 |
| Scheen, AJ; Van Gaal, LF | 2 |
| Hocher, B; Reichetzeder, C; von Websky, K | 1 |
| Bhattacharya, S; Boehm, BO; Grill, V; Johansen, OE; Patel, S; Torjesen, PA; Wetzel, K; Woerle, HJ | 1 |
| Kutoh, E | 1 |
| Friedrich, C; Retlich, S; Sarashina, A; Staab, A; Tadayasu, Y; Takano, M; Tatami, S; Tsuda, Y | 1 |
| Fujita, K; Goto, Y; Gotoh, H; Hasegawa, H; Inagaki, M; Inoue, M; Kimura, K; Nakamura, Y; Oguchi, K; Shimizu, T; Tsuji, M | 1 |
| Anastassiadis, E; Diessel, S; Forst, T; Löffler, A; Pfützner, A | 1 |
| Yamada, T | 1 |
| Shah, R | 1 |
| Moore, N; Pariente, A; Salvo, F | 1 |
| Barnett, AH; Patel, S; von Eynatten, M; Woerle, HJ | 1 |
| Cheetham, SC; Headland, KR; Jones, RB; Klein, T; Mark, M; Vickers, SP | 1 |
| Tibaldi, JM | 1 |
| Crowe, S; Del Prato, S; Gong, Y; Groop, PH; Owens, DR; Patel, S; Taskinen, MR; von Eynatten, M; Woerle, HJ | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Darsalia, V; Klein, T; Larsson, M; Mansouri, S; Nathanson, D; Nyström, T; Olverling, A; Patrone, C; Sjöholm, Å | 1 |
| Dugi, K; Hehnke, U; Heise, T; Larbig, M; Patel, S; Seck, T; Woerle, HJ | 1 |
| Bajaj, M; Gilman, R; Kempthorne-Rawson, J; Lewis-D'Agostino, D; Patel, S; Woerle, HJ | 1 |
| Doupis, J | 1 |
| Barnett, AH; Hehnke, U; Patel, S; Schernthaner, G; von Eynatten, M; Woerle, HJ | 1 |
| Boehm, BO; Dugi, KA; Graefe-Mody, U; Ittrich, C; Mark, M; Woerle, HJ; Zimdahl, H | 1 |
| Alejandre, MJ; Aránega, A; Caba, O; Delgado, JR; Iglesias, J; Irigoyen, A; Linares, A; Martin, M; Ortuño, FM; Palomino, RJ; Perales, S; Prados, JC; Rojas, I; Torres, C | 1 |
| Kong, L; Lai, ZW; Li, C; Liu, J; Sun, H; Wen, X | 1 |
| Jin, D; Sakonjo, H; Takai, S | 1 |
| Ishibashi, Y; Matsui, T; Ojima, A; Sugiura, T; Yamagishi, S | 1 |
| Pratley, RE | 1 |
| Choi, DS; Emser, A; Gong, Y; Mohan, V; Patel, S; Siddiqui, K; Woerle, HJ; Zeng, Z | 1 |
| Chan, KC; Chen, ML; Huang, CN; Peng, CH; Wang, CJ; Yang, YS | 1 |
| McKeage, K | 1 |
| Bailes, Z; Caballero, AE; Del Prato, S; Gallwitz, B; Lewis-D'Agostino, D; Patel, S; Ross, SA; Thiemann, S; von Eynatten, M; Woerle, HJ | 1 |
| Barnett, AH | 2 |
| Dugi, KA; Gallwitz, B; Hehnke, U; Mehlburger, L; Patel, S; Rosenstock, J; von Eynatten, M; Woerle, HJ | 1 |
| Abe, M; Antoku, S; Ito, H; Mifune, M; Nishio, S; Omoto, T; Shinozaki, M; Togane, M | 1 |
| Broedl, UC; DeFronzo, RA; Kaste, R; Lewin, A; Liu, D; Patel, S; Woerle, HJ | 2 |
| Barnett, AH; Gallwitz, B; Groop, PH; Hehnke, U; Laakso, M; Patel, S; Rosenstock, J; Tamminen, I; von Eynatten, M; Woerle, HJ | 1 |
| Bhattacharya, S; Gong, Y; Park, SW; Patel, S; Pinnetti, S; Seck, T; Sheu, WH; Woerle, HJ | 1 |
| Aronson, R | 1 |
| Crowe, S; Kountz, DS; Thrasher, J; von Eynatten, M; Woerle, HJ | 1 |
| Cooper, ME; Groop, PH; Hehnke, U; McGill, JB; Perkovic, V; Rosenstock, J; von Eynatten, M; Wanner, C; Woerle, HJ | 1 |
| Ait-Aissa, K; Ali, M; Kassan, M; Matrougui, K; Trebak, M | 1 |
| Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W | 1 |
| Atsumi, T; Ishizu, A; Kusunoki, Y; Miyoshi, A; Miyoshi, H; Nakamura, A; Nakazawa, D; Shida, H; Tomaru, U; Yamada, M | 1 |
| Bagattin, A; Felix, T; Garbay, S; Heidet, L; Lerner, J; Makinistoglu, MP; Pontoglio, M; Verdeguer, F | 1 |
| Byrjalsen, I; Christiansen, C; Genovese, F; Henriksen, K; Karsdal, MA; Leeming, DJ; Nielsen, MJ; Riis, BJ; Schuppan, D | 1 |
| Abbott, A | 1 |
| Fuchs, H; Greischel, A; Roth, W; Tillement, JP; Urien, S | 1 |
| Rungby, J | 1 |
| Dugi, KA; Graefe-Mody, EU; Heise, T; Hüttner, S; Ring, A; Trommeshauser, D | 1 |
| Fuchs, H; Greischel, A; Jaehde, U; Retlich, S; Staab, A; Withopf, B | 1 |
| Tiwari, A | 1 |
| Deacon, CF; Holst, JJ | 1 |
| Duval, V; Graefe-Mody, U; Jaehde, U; Retlich, S; Staab, A | 1 |
| Li, YX; Sun, Q; Wang, H; Wang, SN | 1 |
| Dugi, KA; Graefe-Mody, EU; Hayashi, N; Horie, Y; Nakashima, M; Sarashina, A; Sesoko, S; Taniguchi, A; Woerle, HJ | 1 |
| Gerich, J | 1 |
| Dugi, KA; Forst, T; Friedrich, C; Graefe-Mody, U; Herbach, K; Ring, A; Uhlig-Laske, B; Woerle, HJ | 1 |
| Graefe-Mody, U; Iovino, M; Ring, A; Rose, P; Woerle, HJ; Zander, K | 1 |
| Dugi, KA; Kubiak, R; Patel, S; Rosenstock, J; Tamminen, I; Taskinen, MR; Woerle, HJ | 1 |
| Barnett, AH; Del Prato, S; Dugi, KA; Huisman, H; Neubacher, D; Woerle, HJ | 1 |
| Beck-Nielsen, H; Byrjalsen, I; Christiansen, C; Gram, J; Hansen, G; Henriksen, K; Karsdal, MA; Perrild, H; Qvist, P; Riis, BJ; Svendsen, OL | 1 |
| Dugi, KA; Forst, T; Graefe-Mody, U; Ring, A; Ritzhaupt, A; Uhlig-Laske, B | 1 |
| Dugi, KA; Espadero, RM; Gomis, R; Jones, R; Woerle, HJ | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Scott, LJ | 1 |
| Gallwitz, B | 1 |
| Traynor, K | 1 |
| Friedrich, C; Graefe-Mody, U; Halabi, A; Heise, T; Port, A; Retlich, S; Ring, A; Woerle, HJ | 1 |
| Toth, PP | 1 |
| Dugi, KA; Graefe-Mody, EU; Hayashi, N; Horie, Y; Kanada, S; Sarashina, A; Taniguchi, A; Watada, H; Woerle, HJ | 1 |
| Dugi, KA; Owens, DR; Swallow, R; Woerle, HJ | 1 |
| Garber, AJ | 1 |
| Jermendy, G | 2 |
| Agrawal, N; Kalra, S; Singh, AK; Unnikrishnan, AG | 1 |
| Deshpande, SS; Ghatak, SB; Panchal, SJ; Patel, DS; Shanker, N; Srivastava, A | 1 |
| Araki, E; Dugi, KA; Gong, Y; Hayashi, N; Horie, Y; Inagaki, N; Kawamori, R; Sarashina, A; von Eynatten, M; Watada, H; Woerle, HJ | 1 |
| Forst, T; Pfützner, A | 1 |
| Fuchs, H; Held, HD; Runge, F | 1 |
| Johansen, OE; Neubacher, D; Patel, S; von Eynatten, M; Woerle, HJ | 1 |
| Cinca, R; Graefe-Mody, U; Retlich, S; Ring, A; Rose, P; Waldhauser, L; Woerle, HJ | 1 |
| Barnett, AH; Emser, A; Patel, S; Schernthaner, G; Troost, J; von Eynatten, M; Woerle, HJ | 1 |
| Neumiller, JJ | 1 |
| Derosa, G; Maffioli, P | 1 |
| Elrod, S; Harrington, C; McLaughlin-Middlekauff, J; Singh-Franco, D | 1 |
| Agrawal, R; Dikshit, SN; Jain, P | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| Neumiller, JJ; Setter, SM | 1 |
| Encinas, J; Hayashi, N; Ohmura, T | 1 |
| Derendorf, H; Graefe-Mody, U; Retlich, S; Singh, RP; Wright, S | 1 |
| Friedrich, C; Graefe-Mody, U; Retlich, S | 1 |
| Doogue, MP; Polasek, TM; Snyder, B | 1 |
| Paquot, N; Scheen, AJ | 1 |
| Bhattacharya, S; Dugi, KA; Gallwitz, B; Patel, S; Rauch, T; Rosenstock, J; von Eynatten, M; Woerle, HJ | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Chen, L; Klein, T; Leung, PS | 1 |
| Meinicke, T; Rafeiro, E; Ross, SA; Toorawa, R; Weber-Born, S; Woerle, HJ | 1 |
| Deeks, ED | 1 |
| Christensen, M; Knop, FK | 1 |
| Arvay, L; Lewin, AJ; Liu, D; Patel, S; von Eynatten, M; Woerle, HJ | 1 |
| Barnett, AH; Harper, R; Patel, S; Thiemann, S; Toorawa, R; von Eynatten, M; Woerle, HJ | 1 |
| McGill, JB; Newman, J; Patel, S; Sauce, C; Sloan, L; von Eynatten, M; Woerle, HJ | 1 |
| Del Prato, S; Forst, T; Gomis, R; Owens, DR; Taskinen, MR; Woerle, HJ | 1 |
| Brown, DX; Choudhury, M; Evans, M | 1 |
| Daniels, K; Patel, S; Thrasher, J; Whetteckey, J | 1 |
| Lajara, R | 1 |
| Araki, E; Dugi, K; Hayashi, N; Horie, Y; Inagaki, N; Kawamori, R; Sarashina, A; Thiemann, S; von Eynatten, M; Watada, H; Woerle, HJ | 1 |
| Doupis, J; Koliaki, C | 1 |
| Haak, T | 1 |
| Stafford, N | 1 |
| Gallwitz, B; Rosenstock, J; Woerle, HJ | 1 |
| Bilo, HJ; Kleefstra, N; van Hateren, KJ | 1 |
| Friedrich, C; Glund, S; Graefe-Mody, U; Kissling, CJ; Lionetti, D; Patel, S; Retlich, S; Righetti, J; Woerle, HJ | 1 |
| Costa, DB; Huberman, MS | 1 |
| Eckhardt, M; Fuchs, H; Guth, B; Himmelsbach, F; Langkopf, E; Lotz, R; Mark, M; Nar, H; Pfrengle, W; Sieger, P; Tadayyon, M; Thomas, L | 1 |
| Eckhardt, M; Himmelsbach, F; Langkopf, E; Mark, M; Tadayyon, M; Thomas, L | 1 |
| Eriksson, JW; Foley, K; Jansson, PA; Lithell, H | 1 |
| Rabl, W; Standl, E; Stemplinger, J; Stiegler, H; Weichenhain, B; Ziegler, AG | 1 |
| Goto, T; Ikuma, K; Kawamura, I; Mutoh, S; Seki, J; Shimoshige, Y; Takakura, S; Yamamoto, T | 1 |
55 review(s) available for quinazolines and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Efficacy and safety of Jentadueto® (linagliptin plus metformin).
Topics: Animals; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Linagliptin. Avoid gliptins!
Topics: Biomarkers; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Immune System; Linagliptin; Pancreatitis; Patient Selection; Purines; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials.
Topics: Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Kidney Diseases; Linagliptin; Purines; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2013 |
[Oral Linagliptin (Trajenta)].
Topics: Contraindications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2013 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2013 |
[Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines | 2013 |
Linagliptin as add-on therapy to insulin for patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Patient Selection; Purines; Quinazolines; Risk Factors; Treatment Outcome | 2013 |
Probable linagliptin-induced liver toxicity: a case report.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Fatigue; Female; Half-Life; Humans; Jaundice; Linagliptin; Metabolic Clearance Rate; Middle Aged; Nausea; Purines; Quinazolines | 2014 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.
Topics: Adult; Aged; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Placebos; Purines; Quinazolines; Randomized Controlled Trials as Topic; Severity of Illness Index | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Linagliptin; Postprandial Period; Purines; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Linagliptin: from bench to bedside.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines; Wound Healing | 2014 |
Linagliptin use in older individuals with type 2 diabetes.
Topics: Aged; Aging; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2014 |
Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2015 |
Linagliptin: an update of its use in patients with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Linagliptin; Purines; Quinazolines | 2014 |
Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2015 |
Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2015 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
Topics: Argentina; Black People; Brazil; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Mexico; Purines; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; United States | 2015 |
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Topics: Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Glucagon-Like Peptide 1; Humans; Insulin-Secreting Cells; Linagliptin; Molecular Structure; Purines; Quinazolines | 2009 |
Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Topics: Animals; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines; Species Specificity | 2009 |
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Humans; Hypoglycemic Agents; Linagliptin; Molecular Structure; Purines; Quinazolines; Xanthine | 2010 |
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Linagliptin: in type 2 diabetes mellitus.
Topics: Adult; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2011 |
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
Topics: Administration, Oral; Animals; Boronic Acids; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Hypoglycemic Agents; Linagliptin; Piperidines; Purines; Quinazolines; Uracil | 2011 |
Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2011 |
Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2011 |
Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2011 |
Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Humans; Incretins; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2011 |
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin | 2011 |
Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines; Treatment Outcome | 2011 |
Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Topics: Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Glyburide; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Pioglitazone; Purines; Quinazolines; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2012 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
Topics: Aged; Angina, Unstable; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Female; Glycated Hemoglobin; Hospitalization; Humans; Linagliptin; Male; Middle Aged; Myocardial Infarction; Patient Safety; Proportional Hazards Models; Prospective Studies; Purines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2012 |
Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Purines; Quinazolines | 2012 |
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Purines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Vildagliptin | 2012 |
The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Aged; Biomarkers; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome; United States | 2012 |
Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor.
Topics: Animals; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Linagliptin; Purines; Quinazolines; Structure-Activity Relationship | 2012 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Review of linagliptin for the treatment of type 2 diabetes mellitus.
Topics: Adult; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2012 |
[Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines; Renal Insufficiency | 2012 |
Clinical pharmacokinetics and pharmacodynamics of linagliptin.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Purines; Quinazolines | 2012 |
Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Linagliptin; Metformin; Purines; Quinazolines; Treatment Outcome | 2012 |
Linagliptin as add-on therapy for type 2 diabetes - an overview.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Purines; Quinazolines | 2012 |
Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2012 |
Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Purines; Quinazolines | 2012 |
Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Practice Guidelines as Topic; Purines; Quinazolines | 2012 |
Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Evaluation; Drug Interactions; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
46 trial(s) available for quinazolines and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Non-alcoholic Fatty Liver Disease; Purines; Quinazolines; Treatment Outcome | 2021 |
Effect of Linagliptin on Incretin-axis and Glycaemic Variability in T1DM.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Purines; Quinazolines; Treatment Outcome | 2018 |
Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years.
Topics: Analysis of Variance; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome; Weight Gain | 2013 |
Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
Topics: Asian People; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome | 2013 |
Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
Topics: Aged; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Placebos; Purines; Quinazolines; Sulfonylurea Compounds | 2013 |
Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Purines; Quinazolines; Treatment Outcome | 2013 |
Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.
Topics: Aged; Albuminuria; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Renin-Angiotensin System; Treatment Outcome | 2013 |
Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Retrospective Studies; Thiazolidinediones; Treatment Outcome | 2013 |
Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2013 |
Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Kidney; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Sulfonylurea Compounds | 2014 |
C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.
Topics: Adult; Aged; Autoimmunity; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds | 2014 |
Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Models, Biological; Purines; Quinazolines | 2013 |
Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes.
Topics: Aged; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Linagliptin; Male; Purines; Quinazolines; Renal Dialysis | 2014 |
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Linagliptin; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Postprandial Period; Proinsulin; Purines; Quinazolines; Risk Factors; Sulfonylurea Compounds | 2014 |
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Thiazolidinediones; Treatment Failure; Treatment Outcome; Weight Gain | 2014 |
Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.
Topics: Aged; Aged, 80 and over; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Incidence; Linagliptin; Male; Purines; Quinazolines; Treatment Outcome | 2014 |
Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin.
Topics: Alleles; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Genetic Predisposition to Disease; Humans; Linagliptin; Purines; Quinazolines; Transcription Factor 7-Like 2 Protein | 2014 |
Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; International Cooperation; Linagliptin; Metformin; Purines; Quinazolines; Treatment Outcome | 2015 |
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Risk; Sulfonylurea Compounds; Time Factors; Young Adult | 2015 |
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Loss | 2015 |
Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Purines; Quinazolines; Sulfonylurea Compounds | 2015 |
Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Gain | 2015 |
Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2015 |
Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes.
Topics: Adipose Tissue; Aged; Blood Glucose; Collagen Type VI; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptide Fragments; Pioglitazone; PPAR gamma; Quinazolines; Thiazolidinediones | 2017 |
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Topics: Administration, Oral; Adult; Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Half-Life; Humans; Linagliptin; Male; Metabolic Clearance Rate; Middle Aged; Purines; Quinazolines; Young Adult | 2009 |
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Topics: Adult; Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Half-Life; Humans; Hypoglycemic Agents; Japan; Linagliptin; Male; Metabolic Clearance Rate; Purines; Quinazolines | 2010 |
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2010 |
Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Cross-Over Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glyburide; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds | 2011 |
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Young Adult | 2011 |
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Linagliptin; Male; Middle Aged; Placebos; Purines; Quinazolines; Treatment Outcome; Young Adult | 2011 |
Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
Topics: Aged; Blood Glucose; Body Composition; Bone Density; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; PPAR gamma; Quinazolines; Thiazolidinediones; Water-Electrolyte Balance; Weight Gain | 2011 |
The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Placebos; Postprandial Period; Purines; Quinazolines; Treatment Outcome; Young Adult | 2011 |
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Pioglitazone; Placebos; Purines; Quinazolines; Thiazolidinediones; Treatment Outcome; Young Adult | 2011 |
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Topics: Adult; Aged; Area Under Curve; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemic Agents; Japan; Linagliptin; Male; Middle Aged; Nonlinear Dynamics; Purines; Quinazolines; Time Factors | 2011 |
Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome; Young Adult | 2011 |
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Inositol; Japan; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2012 |
Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2012 |
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Research Design; Sulfonylurea Compounds; Treatment Failure; Treatment Outcome | 2012 |
Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Linagliptin; Male; Middle Aged; Placebos; Purines; Quinazolines | 2012 |
Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome | 2012 |
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome | 2012 |
Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Renal Insufficiency; Young Adult | 2013 |
Black/African American patients with type 2 diabetes mellitus: study design and baseline patient characteristics from a randomized clinical trial of linagliptin.
Topics: Adult; Aged; Aged, 80 and over; Black or African American; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Treatment Outcome; Young Adult | 2012 |
Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Time Factors | 2013 |
Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
Topics: Black or African American; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Purines; Quinazolines | 2013 |
Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Hypertension; Insulin; Male; Middle Aged; Quinazolines | 1996 |
49 other study(ies) available for quinazolines and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Serum untargeted metabolomics analysis of the mechanisms of evodiamine on type 2 diabetes mellitus model rats.
Topics: Amino Sugars; Animals; Arginine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glutathione; Metabolomics; Nucleotides; Proline; Quinazolines; Rats; Streptozocin; Tryptophan | 2022 |
Imidazo[1,2-c]quinazolines as a novel and potent scaffold of α-glucosidase inhibitors: design, synthesis, biological evaluations, and in silico studies.
Topics: Acarbose; alpha-Glucosidases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Kinetics; Molecular Docking Simulation; Quinazolines; Saccharomyces cerevisiae | 2023 |
Physiologically Based Pharmacokinetic Model of the DPP-4 Inhibitor Linagliptin to Describe its Nonlinear Pharmacokinetics in Humans.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Linagliptin; Purines; Quinazolines | 2020 |
Rutaecarpine exhibits anti-diabetic potential in high fat diet-multiple low dose streptozotocin induced type 2 diabetic mice and in vitro by modulating hepatic glucose homeostasis.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Glucose; Homeostasis; Hypoglycemic Agents; Indole Alkaloids; Liver; Male; Mice, Inbred C57BL; Quinazolines | 2020 |
A pharmacokinetic study on lapatinib in type 2 diabetic rats.
Topics: Animals; Antineoplastic Agents; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Lapatinib; Male; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Tandem Mass Spectrometry | 2018 |
Frailty and diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Purines; Quinazolines | 2013 |
Linagliptin for elderly patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Purines; Quinazolines | 2014 |
Linagliptin for elderly patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Purines; Quinazolines | 2014 |
Linagliptin for elderly patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Purines; Quinazolines | 2014 |
Linagliptin for elderly patients with type 2 diabetes - Authors' reply.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Purines; Quinazolines | 2014 |
Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Hypoglycemic Agents; Inositol; Linagliptin; Male; Peptides; Purines; Quinazolines; Rats; Rats, Zucker; Treatment Outcome; Venoms | 2014 |
Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
Topics: Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Linagliptin; Male; Mice; Mice, Inbred C57BL; Neural Stem Cells; Purines; Quinazolines; Stroke; Structure-Activity Relationship | 2014 |
Serum cytokine profile in patients with pancreatic cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Comorbidity; Cytokines; Deoxycytidine; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking; Tumor Microenvironment | 2014 |
Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Linagliptin; Models, Molecular; Piperidines; Protein Conformation; Purines; Quinazolines; Structure-Activity Relationship; Substrate Specificity; Uracil | 2014 |
Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
Topics: Animals; Atherosclerosis; Blood Glucose; Carotid Arteries; Chemokine CCL2; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; In Vitro Techniques; Insulin; Linagliptin; Malondialdehyde; NADPH Oxidases; Purines; Pyrazines; Quinazolines; Rats, Zucker; Sitagliptin Phosphate; Triazoles; Vasodilation | 2014 |
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Prospective Studies; Purines; Quinazolines; Uric Acid; Xanthine Oxidase | 2014 |
Hibiscus sabdariffa polyphenols alleviate insulin resistance and renal epithelial to mesenchymal transition: a novel action mechanism mediated by type 4 dipeptidyl peptidase.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Epithelial-Mesenchymal Transition; Glucose; Hibiscus; Insulin Receptor Substrate Proteins; Insulin Resistance; Kidney; Linagliptin; Male; Phosphorylation; Polyphenols; Purines; Quinazolines; Rats, Sprague-Dawley; Vimentin | 2014 |
Comparison of the antidiabetic effects of linagliptin among groups with a normal renal function and a mild or severe renal impairment - retrospective observation study of Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Asian People; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Linagliptin; Male; Purines; Quinazolines; Renal Insufficiency; Retrospective Studies | 2015 |
Augmented EGF receptor tyrosine kinase activity impairs vascular function by NADPH oxidase-dependent mechanism in type 2 diabetic mouse.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Cytochrome b Group; Diabetes Mellitus, Type 2; Diabetic Angiopathies; ErbB Receptors; Mice; Mice, Knockout; NADPH Oxidase 4; NADPH Oxidases; Phenylephrine; Quinazolines; Tyrphostins; Vasoconstriction; Vasodilation | 2015 |
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Circulating Neutrophil Extracellular Trap Levels in Well-Controlled Type 2 Diabetes and Pathway Involved in Their Formation Induced by High-Dose Glucose.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; DNA; Dose-Response Relationship, Drug; Extracellular Traps; Glucose; Humans; Hypoglycemic Agents; Middle Aged; Neutrophils; Peroxidase; Polymers; Pyrazines; Pyrroles; Quinazolines; Risk Factors; Spiro Compounds; Time Factors | 2016 |
Human mutations affect the epigenetic/bookmarking function of HNF1B.
Topics: Animals; Cells, Cultured; Chromatin; Diabetes Mellitus, Type 2; DNA; Dogs; Epigenesis, Genetic; Epithelial Cells; Gene Deletion; Green Fluorescent Proteins; Hepatocyte Nuclear Factor 1-beta; Heterozygote; Humans; Kidney; Madin Darby Canine Kidney Cells; Mitosis; Models, Biological; Mutation; Protein Binding; Protein Domains; Quinazolines; Recombinant Fusion Proteins; Temperature | 2016 |
Jentadueto XR for type 2 diabetes.
Topics: Administration, Oral; Biomarkers; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Humans; Hypoglycemic Agents; Purines; Quinazolines; Treatment Outcome | 2016 |
Pharmaceutical futures: a fiendish puzzle.
Topics: Animals; Clinical Trials as Topic; Computer Simulation; Diabetes Mellitus, Type 2; Drug Industry; Gefitinib; Genomics; Glycoproteins; Humans; Models, Biological; Neoplasms; Proteome; Quinazolines; Systems Biology | 2008 |
Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans.
Topics: Algorithms; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Kinetics; Linagliptin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Structure; Protein Binding; Purines; Quinazolines; Rats; Rats, Inbred F344 | 2009 |
Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.
Topics: Animals; Binding Sites; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Linagliptin; Purines; Quinazolines; Rats; Rats, Inbred F344 | 2009 |
Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients.
Topics: Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Linagliptin; Metabolic Clearance Rate; Models, Biological; Protein Binding; Purines; Quinazolines; Tissue Distribution | 2010 |
[Gefitinib improves insulin sensitivity in Wistar diabetes rats models].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gefitinib; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Phosphatidylinositol 3-Kinases; Quinazolines; Rats; Rats, Wistar | 2009 |
Linagliptin approved for type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Humans; Linagliptin; Purines; Quinazolines | 2011 |
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
Topics: Analysis of Variance; Area Under Curve; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Kidney Failure, Chronic; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2011 |
Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Humans; Hypoglycemic Agents; Linagliptin; Patents as Topic; Purines; Quinazolines | 2011 |
Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux.
Topics: Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Biliary Tract; Biological Availability; Biological Transport; Diabetes Mellitus, Type 2; Dibenzocycloheptenes; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Intestinal Mucosa; Linagliptin; Male; Purines; Quinazolines; Quinolines; Rats; Rats, Wistar | 2012 |
Pharmacokinetics of linagliptin in subjects with hepatic impairment.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Linagliptin; Liver Diseases; Male; Middle Aged; Purines; Quinazolines; Severity of Illness Index | 2012 |
[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines; Renal Insufficiency | 2012 |
The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety.
Topics: Blood Proteins; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Linagliptin; Models, Biological; Purines; Quinazolines | 2012 |
Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946.
Topics: Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Kidney Failure, Chronic; Male; Purines; Quinazolines | 2012 |
Gliptin versus a sulphonylurea as add-on to metformin.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Purines; Quinazolines; Sulfonylurea Compounds | 2012 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
Topics: Animals; Apoptosis Regulatory Proteins; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Gene Expression; Hypoglycemic Agents; Inflammation Mediators; Insulin; Insulin Secretion; Islets of Langerhans; Linagliptin; Lipids; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Pancreatitis; Purines; Quinazolines; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Tissue Culture Techniques | 2012 |
Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines; Sulfonylurea Compounds | 2012 |
Response letter to D. Singh-franco et al.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Metformin; Purines; Quinazolines; Thiazolidinediones | 2012 |
New drug for type 2 diabetes is no better than older, cheaper treatments, says institute.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Germany; Humans; Linagliptin; Purines; Quinazolines | 2012 |
Preregistration of study design and non-inferiority margin - Authors' reply.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Purines; Quinazolines; Sulfonylurea Compounds | 2013 |
Preregistration of study design and non-inferiority margin.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Purines; Quinazolines; Sulfonylurea Compounds | 2013 |
Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Glyburide; Humans; Lung Neoplasms; Pioglitazone; Quinazolines; Thiazolidinediones | 2006 |
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.
Topics: Administration, Oral; Animals; Caco-2 Cells; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Humans; Hypoglycemic Agents; Linagliptin; Macaca fascicularis; Macaca mulatta; Male; Models, Molecular; Piperidines; Purines; Quinazolines; Rats; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship | 2007 |
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with oth
Topics: Animals; Antigens, Neoplasm; Biomarkers, Tumor; Caco-2 Cells; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Endopeptidases; Gelatinases; Humans; Hypoglycemic Agents; Inhibitory Concentration 50; Linagliptin; Male; Membrane Proteins; Mice; Protease Inhibitors; Purines; Quinazolines; Rats; Rats, Wistar; Rats, Zucker; Serine Endopeptidases; Xanthines | 2008 |
[Alström syndrome--a rare disease of diabetic association].
Topics: Adult; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diagnosis, Differential; DNA Mutational Analysis; Humans; Male; Obesity; Optic Atrophy; Quinazolines; Retinitis Pigmentosa; Second Messenger Systems; Syndrome | 1997 |
The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Models, Animal; Enzyme Inhibitors; Male; Quinazolines; Rats; Rats, Zucker | 2000 |